Premium
Advances in the understanding and management of angioimmunoblastic T‐cell lymphoma
Author(s) -
De Leval Laurence,
Gisselbrecht Christian,
Gaulard Philippe
Publication year - 2010
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.08003.x
Subject(s) - angioimmunoblastic t cell lymphoma , medicine , lymphoma , clinical trial , disease , peripheral t cell lymphoma , pathological , oncology , pathology , t cell , immunology , immune system
Summary Angioimmunoblastic T‐cell lymphoma (AITL) is a distinct peripheral T‐cell lymphoma (PTCL) entity with peculiar clinical and pathological features. The recent identification of follicular helper T (T FH ) cell as the cell of origin of this neoplasm represents a major step in our understanding of the pathobiological characteristics of the disease and should, in the future, clarify the diagnostic criteria for AITL and help to delineate its spectrum, especially from PTCL, not otherwise specified (PTCL, NOS). Deciphering the pathogenesis of the disease is needed to identify targets for new therapies that are expected to improve the poor outcome of AITL patients, when treated with conventional chemotherapy regimens. In this respect, efforts will be needed to evaluate promising innovative therapies in prospective clinical trials.